OPUS BIOSCIENCES
LIVE

Serial Number

99187647

Owner

Opus Biosciences, Inc.

Attorney

Michael W. Schroeder

First Use Date

Mar 23, 2023

Filing Date

May 15, 2025

Add to watchlist:

No watchlists yet
View on USPTO

OPUS BIOSCIENCES Trademark

Serial Number: 99187647

OPUS BIOSCIENCES is a trademark filed by Opus Biosciences, Inc. on May 15, 2025. The trademark is classified under Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Opus Biosciences, Inc. (2 trademarks)

4006 CAMINITO TERVISO
San Diego, CA 92122

Entity Type: 03

Trademark Details

Filing Date

May 15, 2025

Registration Date

Not Registered

First Use Anywhere

March 23, 2023

First Use in Commerce

December 29, 2023

Goods & Services

Product design and development in the field of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications; Product design and development in the field of lipid nanoparticle (LNP) compositions for the delivery of nucleic acid-based therapeutics, including mRNA, siRNA, and DNA; Design and development of software and hardware for optimization and customization of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications; Research and development of technology in the field of artificial intelligence-based software tools for lipid discovery, pharmaceutical formulation, and delivery optimization; Providing temporary use of non-downloadable cloud-based software for designing, modeling, and deploying therapeutic delivery systems; Medical and scientific research in the field of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications and lipid nanoparticle (LNP) compositions for the delivery of nucleic acid-based therapeutics; Research and development in the field of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications and lipid nanoparticle (LNP) compositions for the delivery of nucleic acid-based therapeutics; Technology consultation and research in the field of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications and lipid nanoparticle (LNP) compositions for the delivery of nucleic acid-based therapeutics

Filing History

REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Apr 27, 2026 RCSC
ASSIGNED TO EXAMINER
Apr 24, 2026 DOCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 3, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 3, 2025 GNSL
SUSPENSION LETTER WRITTEN
Oct 3, 2025 CNSL
ASSIGNED TO EXAMINER
Sep 29, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 24, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
May 15, 2025 MAFR
NEW APPLICATION ENTERED
May 15, 2025 NWAP